Volume 15, Number 5—May 2009
Postoperative Panophthalmitis Caused by Whipple Disease
To the Editor: The clinical spectrum of Whipple disease has widely expanded since its etiologic agent, Tropheryma whipplei, was isolated in 2000 (1). Systematic 16S rDNA sequencing unexpectedly identified T. whipplei in patients for whom blood cultures were negative for endocarditis, spondylitis, and uveitis (2). Features common to these conditions and to Whipple disease include long-standing, unexplained arthralgia and deterioration of the patient’s condition after treatment with immunosuppressive drugs (2). We report an unexpected case of postoperative panendophthalmitis identified by systematic 16S rDNA sequencing of a vitreous sample in a patient who had unexplained arthralgia and had been given topical corticosteroids after cataract surgery.
A 78-year-old woman in France underwent left eye phacoemulsification with intraocular lens implantation in May 2005 and retinal surgery followed by local corticoid application in April 2006. She had experienced cortisone-resistant polyarthralgia for 2 years before the first surgery. In July 2006, she showed decreased visual acuity (20/1,000) and a painful, red eye. Chronic postoperative endophthalmitis was suspected, and the patient underwent anterior chamber paracentesis (ACP). Parameters included 0.614 × 109 eosinophils/L in the blood and an erythrocyte sedimentation rate of 70 mm in the first hour.
Sequencing of 16S rDNA of the ACP specimen showed 99.9% similarity with that of T. whipplei (GenBank accession no. AJ551273). A specific PCR confirmed this result in the ocular sample and detected T. whipplei in saliva and stool samples, whereas blood and cerebrospinal fluid were negative for the organism by PCR. Duodenal biopsy specimens were negative by periodic acid–Schiff staining, specific immunohistochemical analysis, and PCR.
The patient was treated with topical corticosteroids, cycloplegic drugs, doxycycline (200 mg/d), hydroxychloroquine (200 mg 3×/d), and sulfamethoxazole/trimethoprim (1,600 mg and 320 mg 3×/d) (2). She was hospitalized for 7 days in the ophthalmology department and for 4 days in the infectious disease department. At 8-month follow-up, visual acuity had improved (20/50) despite intraocular inflammation with a Tyndall effect, moderate capsular opacification, decreased vitreitis, macular edema, and retinal macular abnormalities shown by optical coherence tomography. T. whipplei DNA was again not detected by PCR in saliva and stool samples at 8-month follow-up, and the patient remained free of symptoms at 16-month follow-up when treatment was stopped.
Diagnosis of Whipple disease uveitis was confirmed by detection of T. whipplei DNA in the ocular sample by 2 laboratories that used 2 molecular targets and negative controls. T. whipplei was identified by 16S rDNA sequencing and by detection of T. whipplei–specific repeat sequences. Further investigations detected T. whipplei in saliva and stool samples. Uveitis was the initial manifestation of Whipple disease, although patient evaluation showed a 2-year history of idiopathic, corticoresistant polyarthralgia described as a hallmark of Whipple disease (2). Initial unexplained eosinophilia in blood was observed, as in several confirmed cases of Whipple disease (2).
Uveitis has been reported in Whipple disease (2), but <20 patients had T. whipplei in a diseased eye (Table). T. whipplei has been found by periodic acid–Schiff staining of foamy macrophages, electron microscopy, and immunocytochemical detection in ocular monocytes (3–10). Detection of T. whipplei DNA (6–10) has been confirmed by sequencing in only 2 patients, including the case reported herein.
Diagnosis of T. whipplei uveitis in our patient was made 3 months after ocular surgery. The patient’s condition was diagnosed as chronic postoperative panendophthalmitis, which raised the issue of nosocomial transmission of T. whipplei. We have reported a correlation between diagnosis of T. whipplei uveitis and a history of ocular surgery (7). By reanalyzing detailed published reports, we found that 11 of 19 patients with intraocular demonstration of T. whipplei had a history of ocular surgery before documentation of Whipple disease uveitis (Table). T. whipplei has not been reported as being responsible for nosocomial infection. Items used during the patient’s ocular surgery were confirmed to be disposable and nonreused.
Topical drops of corticosteroids commonly applied during cataract surgery for intraocular lens implantation penetrate ocular structures. An alternative hypothesis is that corticosteroids applied during ocular surgery reactivate a latent ocular infection. Our review indicated that 13 of 19 patients with documented T. whipplei uveitis had received topical or systemic corticosteroids before the diagnosis (Table) (7). Worsening of Whipple disease has been reported in patients receiving corticoid therapy for arthralgia (10). We speculate that our patient had an asymptomatic ocular infection before surgery.
This case shows that ocular surgery and use of topical corticosteroids that penetrate ocular structures could reactivate a latent T. whipplei ocular infection. We suggest that patients with postoperative panendophthalmitis be tested for T. whipplei by PCR.
M.D., F.F., and D.R. were supported by Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes; D.D. was supported by Assistance Publique–Hôpitaux de Marseille.
- Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, Cultivation of the bacillus of Whipple’s disease. N Engl J Med. 2000;342:620–5.
- Fenollar F, Puechal X, Raoult D. Whipple’s disease. N Engl J Med. 2007;356:55–66.
- Font RL, Rao NA, Issarescu S, McEntee WJ. Ocular involvement in Whipple’s disease: light and electron microscopic observations. Arch Ophthalmol. 1978;96:1431–6.
- Durant WJ, Flood T, Goldberg MF, Tso MO, Pasquali LA, Peyman GA. Vitrectomy and Whipple’s disease. Arch Ophthalmol. 1984;102:848–51.
- Selsky EJ, Knox DL, Maumenee AE, Green WR. Ocular involvement in Whipple’s disease. Retina. 1984;4:103–6.
- Williams JG, Edward DP, Tessler HH, Persing DH, Mitchell PS, Goldstein DA. Ocular manifestations of Whipple disease: an atypical presentation. Arch Ophthalmol. 1998;116:1232–4.
- Drancourt M, Berger P, Terrada C, Bodaghi B, Conrath J, Raoult D, High prevalence of fastidious bacteria in 1,520 cases of uveitis of unknown etiology. Medicine (Baltimore). 2008;87:167–76.
- Davis JL, Miller DM, Ruiz P. Diagnostic testing of vitrectomy specimens. Am J Ophthalmol. 2005;140:822–9.
- Knox DL, Green WR, Troncoso JC, Yardley JH, Hsu J, Zee DS. Cerebral ocular Whipple’s disease: a 62-year odyssey from death to diagnosis. Neurology. 1995;45:617–25.
- Mahnel R, Kalt A, Ring S, Stallmach A, Strober W, Marth T. Immunosuppressive therapy in Whipple’s disease patients is associated with the appearance of gastrointestinal manifestations. Am J Gastroenterol. 2005;100:1167–73.
- Table. Characteristics of 19 patients with Whipple disease uveitis documented by presence of Tropheryma whipplei in a diseased eye
Suggested citation for this article: Drancourt M, Fenollar F, Denis D, Raoult D. Postoperative panophthalmitis caused by Whipple disease [letter]. Emerg Infect Dis [serial on the Internet]. 2009 May [date cited]. Available from http://wwwnc.cdc.gov/eid/article/15/5/08-1209
Please use the form below to submit correspondence to the authors or contact them at the following address:
Didier Raoult, Unité des Rickettsies, Faculté de Médecine, Université de la Méditerranée, 27 Blvd Jean Moulin, 13385 Marseille Cedex 5, France
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 16, 2010
- Page last updated: December 16, 2010
- Page last reviewed: December 16, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)